CymaBay Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Sujal A. Shah
- Full Time Employees
- 101
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 7575 Gateway Boulevard Newark CA United States of America 94560
- IPO Date
- Feb 3, 2014
- CIK
- 0001042074
- Website
- cymabay.com
- Similar Companies
- Business
- CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and providing innovative therapies for patients with liver and other chronic diseases with high unmet medical needs. Its primary product is seladelpar, a potent, selective, orally active peroxisome proliferator-activated receptor delta (PPARδ) agonist developed for the treatment of primary biliary cholangitis (PBC), an autoimmune liver disease, including associated pruritus. The company’s product pipeline also includes additional investigational drugs and lead candidates targeting liver and other chronic conditions, such as inflammation and metabolic disorders. Founded in 1988 and headquartered in Newark, California, CymaBay operates primarily within the biopharmaceutical and pharmaceutical manufacturing industry segments. In a major strategic development, CymaBay Therapeutics was acquired by Gilead Sciences, Inc. in March 2024 for approximately $4.3 billion in total equity value, with a tender offer price of $32.50 per share. This acquisition followed the successful completion of clinical trials and regulatory submissions for seladelpar, including the FDA granting priority review and the European Medicines Agency accepting the marketing authorization application for seladelpar in PBC. This transaction aligns with Gilead’s strategy to expand its liver disease portfolio and leverages its global expertise in developing and commercializing transformative therapies for liver conditions. The acquisition strengthened CymaBay’s operational and commercial capacities to bring seladelpar to market more effectively. CymaBay’s prior key operational focus included raising breakthrough therapy designations, achieving positive phase 3 trial results, and positioning seladelpar as a potential best-in-disease therapy for PBC. CymaBay’s products and research pipeline address liver diseases and chronic inflammatory and metabolic disorders, with a scientific emphasis on selective PPAR agonists. Its lead candidate, seladelpar, represents a novel therapeutic approach for treating autoimmune liver disease by modulating nuclear receptors. The company’s business activities, including clinical development, regulatory interactions, and strategic partnerships, have been concentrated in the United States, with expanding global regulatory efforts in Europe. The acquisition by Gilead reinforces CymaBay’s reach into international markets and complements Gilead’s portfolio of liver disease treatments, reflecting a major shift in ownership and operational capabilities effective since early 2024. Thus, CymaBay Therapeutics, Inc. presently operates as a wholly owned subsidiary of Gilead Sciences, continuing its focus on liver and chronic disease therapies with its principal product seladelpar advancing toward global market authorization and commercial launch. This transition marks the latest major phase in the company’s strategic evolution and development trajectory.
Gilead Sciences Announces Completion of Acquisition of CymaBay
CymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis
CymaBay Therapeutics Inc. (CBAY) Reports Q4 Loss, Misses Revenue Estimates
CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update
The New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary Cholangitis
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CYMABAY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CymaBay Therapeutics, Inc. - CBAY
Why Gilead Sciences Is Buying CymaBay Therapeutics for $4.3 Billion
Shareholder Alert: Ademi LLP investigates whether CymaBay Therapeutics, Inc. has obtained a Fair Price in its transaction with Gilead
Why is CymaBay (CBAY) Stock Up 25% Today?
CBAY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CymaBay Therapeutics, Inc. Is Fair to Shareholders
Gilead to buy CymaBay Therapeutics for $4.3 billion
CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis
Drugmaker Gilead to acquire CymaBay for $4.3 bln
Gilead strikes deal to acquire CymaBay for $4.3 billion
Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
CymaBay Therapeutics to Participate in Upcoming Investment Conferences
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
New Published Data Demonstrates Correlation Between Itch Cytokine Interleukin-31 Reduction and Pruritis Improvement in Primary Biliary Cholangitis in Phase 3 Post-Hoc Analysis of CymaBay's Seladelpar
CymaBay Therapeutics to Present at the 42nd Annual JP Morgan Healthcare Conference 2024